# OnCo record uridine-triacetate (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/uridine-triacetate/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "uridine-triacetate" ;
  schema:name "Uridine triacetate"@en ;
  schema:alternateName "Xuriden (hereditary orotic aciduria formulation)"@en, "Vistogard" ;
  schema:description "Uridine triacetate (Vistogard) is an oral antidote for fluorouracil or capecitabine overdose, or for dangerously early severe toxicity from these drugs, and must be started within four days of the chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/uridine-triacetate/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Uridine_triacetate> ;
  schema:citation <https://doi.org/10.1002/cncr.30321>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=269f7363-63ed-444e-85f1-f0009e44818b>, <https://www.cancer.gov/about-cancer/treatment/drugs/uridinetriacetate> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Pyrimidine analogue antidote (oral)" ;
  onco:approval "US 2015: Emergency treatment after fluorouracil or capecitabine overdose or early-onset severe toxicity within 96 hours" ;
  onco:related <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/serb-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/vistogard-studies-1-2/> .